Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,679 questions · 1,720 findings · 335 reviews · Headline outcomes only

No studies found 192 · 11.2%GRADE not reported 75 · 4.4%Very low 526 · 30.6%Low 504 · 29.3%Moderate 305 · 17.7%High 118 · 6.9%

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

DFS: hormone receptor‐negativemedian · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Overall survival: Median length of · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Febrile neutropenia · patients with early breast cancer

Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Diarrhoea · patients with early breast cancer

Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Hand‐foot syndrome · patients with early breast cancer

Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Tafamidis vs placebo

Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP

It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).

1 finding from 1 review